June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Antimicrobial efficacy of netilmicin against Staphylococci administered two or four times a day.
Author Affiliations & Notes
  • Cristina Zappulla
    Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio, Aci Sant'Antonio, Catania, Italy
  • Maria Cristina Curatolo
    Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio, Aci Sant'Antonio, Catania, Italy
  • Andrea Sudano Roccaro
    Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio, Aci Sant'Antonio, Catania, Italy
  • MARIA GRAZIA MAZZONE
    Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio, Aci Sant'Antonio, Catania, Italy
  • Carmela Giovanna Spoto
    Research, Preclinical Development and Patents, SIFI S.p.A., Lavinaio, Aci Sant'Antonio, Catania, Italy
  • Footnotes
    Commercial Relationships   Cristina Zappulla SIFI S.p.A., Code E (Employment); Maria Cristina Curatolo SIFI S.p.A., Code E (Employment); Andrea Sudano Roccaro SIFI S.p.A., Code E (Employment); MARIA MAZZONE SIFI S.p.A., Code E (Employment); Carmela Spoto SIFI S.p.A., Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2113 – F0129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cristina Zappulla, Maria Cristina Curatolo, Andrea Sudano Roccaro, MARIA GRAZIA MAZZONE, Carmela Giovanna Spoto; Antimicrobial efficacy of netilmicin against Staphylococci administered two or four times a day.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2113 – F0129.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Netilmicin is an aminoglycoside antibiotic indicated for the treatment of bacterial ocular infections of the anterior segment of the eye and ocular adnexa. Combined with dexamethasone, it’s indicated in inflammatory ocular conditions including post-operative cases. Marketed formulations with netilmicin and dexamethasone have a dosing schedule of 4 administrations per day. To predict clinical efficacy of netilmicin when administered 2 (b.i.d.) or 4 (q.i.d.) times a day, killing kinetic experiments were performed against S. aureus (S.a.) and S. epidermidis (S.e.) using a standard and a pulsed protocol to mimic the posology scheme used in human.

Methods : S.a. 6538 and S.e. 12228 ATCCs grown to reach 108 cfu/ml on supplemented Mueller-Hinton (MH) broth were then diluted to 106 cfu/ml in the same broth containing 32 µg/ml netilmicin. An antibiotic-free control was similarly inoculated.
Standard protocol: at 0, 1, 2, 6, 12 and 24h, 0.1ml was diluted in phosphate-buffered saline, inoculated onto MH agar plates and incubated at 37°C for 24h, to determine viable cfu/ml.
Pulsed protocol: in the b.i.d. regimen, bacteria were exposed to netilmicin at 0 and 12h while in the q.i.d. regimen, 4 exposures were carried out every 4h along the 12h. In both protocols, contact time of bacteria with netilmicin was 2h. At the end of this period, 0.1ml of each sample were processed as above. Data represent mean±SEM of log10 cfu/ml. Statistical analysis were sought by unpaired t-test.

Results : In the standard protocol, netilmicin showed a bactericidal effect against S.a. at 6h (5 log10 decrease) and this activity is stronger at 12 and 24h (6 log10 decrease). Moreover, netilmicin confirmed bactericidal effect against S.e., and importantly this activity starts 1h after exposure (3 log10 decrease). Data obtained in the pulsed protocol, showed that netilmicin retains its bactericidal effect against S.a. (Fig.1A) and S.e. (Fig.1B) when administered b.i.d. or q.i.d. within 12h (6 log10 decrease) and also at 24h, i.e. after 12h washout.

Conclusions : Interestingly, pulsed protocol demonstrated that bactericidal effect of netilmicin against Staphylococci is maintained unchanged when administered 2 or 4 times a day. Therefore, in order to reduce the antibiotic resistance and improve the patient’s compliance, the hypothesis to reduce the posology of marketed products containing netilmicin could be taken into account.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×